Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this work is to compare the clinical outcomes of letrozole with laparoscopic ovarian drilling (LOD) in patients with clomiphene-citrate-resistant polycystic ovary syndrome (PCOS).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group A Letrozole group | Experimental | 2.5 mg letrozole oral tablets will be administered on the 2nd -3rd day of menses and then every day for 5 days. |
|
| Group B laparoscopic ovarian drilling group | Active Comparator | bilateral laparoscopic ovarian drilling, each ovary will be cauterized at 4 points, each for 4 sec at 40 W, at a depth of 7-8 mm and a diameter of 3-5 mm, using a monopolar electrosurgical needle according to the size of each ovary. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| group A 2.5 mg letrozole oral tablets | Drug | 2.5 mg letrozole oral tablets will be administered on the 2nd-3rd day of menses and then every day for 5 days. Treatment will be repeated for up to three cycles if the patient failed to conceive. |
| Measure | Description | Time Frame |
|---|---|---|
| OVULATION RATE | SERUM PROGESTERON LEVEL | 7 DAYS BEFORE NEXT MENSES |
| Measure | Description | Time Frame |
|---|---|---|
| BIOCHEMICAL PREGNANCY RATE | BY SERUM HCG | AFTER 30 DAYS OF INTERVENTION |
| CLINICAL PREGNANCY RATE | BY FETAL HEART RATE MONITORING BY ULTRASOUND SCAN |
Not provided
Inclusion Criteria:
Exclusion Criteria:
1- Infertility induced by reasons other than PCOS. 2- uterine cavity lesions or ovarian cyst. 3- >40 years old. 4- body mass index (BMI) >26 kg/m2. 5- contraindications to general anesthesia. 6- history of pelvic surgery. 7- other endocrine diseases. 8- a history of liver or kidney disease.
-
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ahmed Abdelshafy, MD | Contact | 00201223266380 | ahmedshafy@hotmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ain shams university maternity hospital | Recruiting | Cairo | 25187 | Egypt |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36165742 | Derived | Franik S, Le QK, Kremer JA, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2022 Sep 27;9(9):CD010287. doi: 10.1002/14651858.CD010287.pub4. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000077289 | Letrozole |
| ID | Term |
|---|---|
| D009570 | Nitriles |
| D009930 | Organic Chemicals |
| D014230 | Triazoles |
| D001393 | Azoles |
| D006573 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| laparoscopic ovarian drilling | Procedure | Bilateral laparoscopic ovarian drilling, each ovary will be cauterized at 4 points, each for 4 sec at 40 W, at a depth of 7-8 mm and a diameter of 3-5 mm, using a monopolar electrosurgical needle according to the size of each ovary. |
|
| AT 6 WEEKS GESTATION |
| Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |